Navigation Links
Novavax to Join Russell 3000 Index
Date:6/26/2008

ROCKVILLE, Md., June 26 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that as of the close of the market Friday, June 27th, it will be included in the Russell 3000 Index, comprised of 3000 of the largest and most liquid stocks based and traded in the United States. Membership in the Russell 3000, which remains in place for a minimum of one year, means the common stock of Novavax will also be automatically included in the small cap Russell 2000 Index.

The Russell 3000 Index is widely used by investment managers and institutional investors for Index funds and as benchmarks for both passive and active investments strategies. The Russell 3000 Index also serves as the U.S. component of the Russell Global Index.

Novavax, Inc. is a clinical-stage biotechnology company creating novel vaccines to address a broad range of infectious diseases worldwide using advanced proprietary virus-like particle (VLP) technology. The Company creates VLPs by genetically engineering three-dimensional, nanostructures, which incorporate immunologically important lipids and recombinant proteins. Novavax' VLPs resemble a virus by lack the genetic material that would cause infection. Using the Company's proprietary virus-like particle (VLP) technologies, Novavax is developing vaccines to protect against H5N1 pandemic influenza, seasonal flu and other viral diseases. The Company also utilizes a unique portable manufacturing system that allows for rapid production of vaccines requiring less infrastructure and represents a potential simpler and more efficient approach to vaccine production. Additional information about Novavax is available at http://www.novavax.com and in the Company's various filings with the Securities and Exchange Commission.

Forward Looking Statements

Statements herein relating to future financial or business performance, conditions or strategies and other financial and business matters, including expectations regarding revenues, operating expenses, cash burn, and clinical developments and anticipated milestones are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Novavax cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including the Company's ability to progress any product candidates in preclinical or clinical trials; the scope, rate and progress of its preclinical studies and clinical trials and other research and development activities; clinical trial results; even if the data from preclinical studies or clinical trials is positive, the product may not prove to be safe and efficacious; Novavax's pilot plant facility is subject to extensive validation and FDA inspections, which may result in delays and increases costs; the effect or outcome of the Company's decision to sell Estrasorb(R); the human capital and other costs Novavax will incur to exit the manufacturing facility; our ability to enter into future collaborations with industry partners and the terms, timing and success of any such collaboration; the cost of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; our ability to obtain rights to technology; competition for clinical resources and patient enrollment from drug candidates in development by other companies with greater resources and visibility; our ability to obtain adequate financing in the future through product licensing, co-promotional arrangements, public or private equity or debt financing or otherwise; general business conditions; competition; business abilities and judgment of personnel; and the availability of qualified personnel. Further information on the factors and risks that could affect Novavax's business, financial conditions and results of operations, is contained in Novavax's filings with the U.S. Securities and Exchange Commission, which are available at http://www.sec.gov. These forward-looking statements speak only as of the date of this press release, and Novavax assumes no duty to update forward-looking statements.


'/>"/>
SOURCE Novavax, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Novavax CEO to Present at Piper Jaffray Europe Conference, London, UK
2. Novavax CEO to Present at FBR Capital Markets 12th Annual Spring Investor Conference
3. Novavax CEO to Present at ACUMENBioFins 5th Annual Global Healthcare Conference
4. Novavax Reports First Quarter 2008 Financial Results
5. Novavax Announces Release Date of 2008 First Quarter Financial Results and Investor Conference Call
6. Novavax Opens Its First U.S. Vaccine Plant
7. Novavax CEO to Present at the World Vaccine Congress 2008
8. Graceway Pharmaceuticals, LLC(TM) Announces Completed Acquisition of All Assets Related to Estrasorb(R) Product Line in North America From Allergan, Inc. (NYSE: AGN) and Novavax, Inc. (Nasdaq: NVAX)
9. Novavax Enters Into Estrasorb(R) Asset Sale and Supply Agreements with Graceway Pharmaceuticals, LLC
10. Novavax CEO to Present at BIO CEO & Investor Conference
11. Cardium Selected for Inclusion in Russell Microcap Index
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... ... May 23, 2016 , ... The need for blood donations in South Texas and across the ... Texas Blood & Tissue Center, blood donations are on the decline. In fact, donations across ... down 21 percent in South Texas in the last four years alone. , There is ...
(Date:5/23/2016)... Oxitec CEO Hadyn Parry will testify ... before the United States House Committee on Science, Space and ... controlling the spread of the Aedes aegypti mosquito, ... (Logo: http://photos.prnewswire.com/prnh/20150630/227348 ) Oxitec has pioneered ... in Brazil , Panama ...
(Date:5/23/2016)... ... May 23, 2016 , ... Foresight Institute , a ... winners for the 2015 Foresight Institute Feynman Prizes. , These prestigious prizes, ... one for experiment and the other for theory in nanotechnology. Prof. Markus J. ...
(Date:5/20/2016)... ... ... Kablooe Design, a leading provider of product design and development services to ... business. “We have worked hard to build long-term relationships,” says President and CEO, Tom ... of serving their product design and development needs through the years.” , Kablooe has ...
Breaking Biology Technology:
(Date:3/31/2016)... March 31, 2016  Genomics firm Nabsys has completed ... Barrett Bready , M.D., who returned to the ... original technical leadership team, including Chief Technology Officer, ... Development, Steve Nurnberg and Vice President of Software and ... company. Dr. Bready served as CEO of ...
(Date:3/22/2016)... March 22, 2016 ... Sensors Market for Consumer Industry by Type (Image, ... Application (Communication & IT, Entertainment, Home Appliances, ... Forecast to 2022", published by MarketsandMarkets, the ... to reach USD 26.76 Billion by 2022, ...
(Date:3/18/2016)... March 18, 2016 --> ... Biometrics, ICT, Manned & Unmanned Vehicles, Physical infrastructure and Perimeter ... companies in the border security market and the continuing migration ... Europe has led visiongain to publish ... success. --> defence & security companies in ...
Breaking Biology News(10 mins):